A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

Moderna was recently told that the Health and Human Services Department (HHS) had withdrawn a $766million grant awarded by ...

The data showed a surprisingly compelling overall survival (OS) benefit. TheBraftovi combination regimen received Food and ...

Pfizer has shared positive survival results from a late-stage study of its Braftovi (encorafenib) regimen in patients with ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...